196 related articles for article (PubMed ID: 12941763)
1. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Larsen PJ; Jensen PB; Sørensen RV; Larsen LK; Vrang N; Wulff EM; Wassermann K
Diabetes; 2003 Sep; 52(9):2249-59. PubMed ID: 12941763
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
3. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
[TBL] [Abstract][Full Text] [Related]
4. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Pickavance LC; Brand CL; Wassermann K; Wilding JP
Br J Pharmacol; 2005 Feb; 144(3):308-16. PubMed ID: 15655531
[TBL] [Abstract][Full Text] [Related]
5. A peroxisome proliferator-activated receptor gamma agonist influenced daily profile of energy expenditure in genetically obese diabetic rats.
Yoshida Y; Ichikawa M; Ohta M; Kanai S; Kobayash M; Ichimaru Y; Shimazoe T; Watanabe S; Funakoshi A; Miyasak K
Jpn J Pharmacol; 2002 Mar; 88(3):279-84. PubMed ID: 11949882
[TBL] [Abstract][Full Text] [Related]
6. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350
[TBL] [Abstract][Full Text] [Related]
7. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
8. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R
Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088
[TBL] [Abstract][Full Text] [Related]
9. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
Lee HJ; Choi SS; Park MK; An YJ; Seo SY; Kim MC; Hong SH; Hwang TH; Kang DY; Garber AJ; Kim DK
Biochem Biophys Res Commun; 2002 Aug; 296(2):293-9. PubMed ID: 12163016
[TBL] [Abstract][Full Text] [Related]
11. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
Liang F; Wang F; Zhang S; Gardner DG
Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation.
Ye JM; Doyle PJ; Iglesias MA; Watson DG; Cooney GJ; Kraegen EW
Diabetes; 2001 Feb; 50(2):411-7. PubMed ID: 11272155
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.
Egerod FL; Nielsen HS; Iversen L; Thorup I; Storgaard T; Oleksiewicz MB
Biomarkers; 2005; 10(4):295-309. PubMed ID: 16240504
[TBL] [Abstract][Full Text] [Related]
18. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.
Kubota N; Terauchi Y; Miki H; Tamemoto H; Yamauchi T; Komeda K; Satoh S; Nakano R; Ishii C; Sugiyama T; Eto K; Tsubamoto Y; Okuno A; Murakami K; Sekihara H; Hasegawa G; Naito M; Toyoshima Y; Tanaka S; Shiota K; Kitamura T; Fujita T; Ezaki O; Aizawa S; Kadowaki T
Mol Cell; 1999 Oct; 4(4):597-609. PubMed ID: 10549291
[TBL] [Abstract][Full Text] [Related]
19. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
[TBL] [Abstract][Full Text] [Related]
20. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
